Edition:
United Kingdom

Alembic Pharmaceuticals Ltd (ALEM.NS)

ALEM.NS on National Stock Exchange of India

591.40INR
9:59am GMT
Change (% chg)

Rs-4.95 (-0.83%)
Prev Close
Rs596.35
Open
Rs598.00
Day's High
Rs600.00
Day's Low
Rs581.70
Volume
113,613
Avg. Vol
62,445
52-wk High
Rs664.00
52-wk Low
Rs414.40

Latest Key Developments (Source: Significant Developments)

Alembic Pharmaceuticals Gets US FDA Nod For Pramipexole Dihydrochloride Extended-Release Tablets
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Alembic Pharmaceuticals Ltd ::SAYS CO GOT US FDA APPROVAL FOR PRAMIPEXOLE DIHYDROCHLORIDE EXTENDED-RELEASE TABLETS.  Full Article

Alembic Pharmaceuticals Says Got Zero Form 483s Post USFDA Inspection At Co's API Facility At Panelav
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Alembic Pharmaceuticals Ltd ::ALEMBIC PHARMACEUTICALS SAYS USFDA CONDUCTED INSPECTION AT CO'S API FACILITY AT PANELAV FROM 17TH DECEMBER, 2018 TO 19TH DECEMBER, 2018.SAYS THERE WERE ZERO 483S POST USFDA INSPECTION.  Full Article

Alembic Pharmaceuticals gets USFDA Nod For Candesartan Cilexetil Tablets
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - Alembic Pharmaceuticals Ltd ::RECEIVED US FOOD & DRUG ADMINISTRATION (USFDA) APPROVAL FOR CANDESARTAN CILEXETIL TABLETS USP, 4 MG, 8 MG, AND 16 MG..CANDESARTAN CILEXETIL TABLETS INDICATED FOR TREATMENT OF HYPERTENSION AND HEART FAILURE.  Full Article

Alembic Pharmaceuticals To Consider Fresh Proposal For Issue Of NCDs On Private Placement Basis
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Alembic Pharmaceuticals Ltd ::BOARD ON SEPT 10 HAD APPROVED ISSUE OF NCDS OF UPTO 3 BILLION RUPEES ON PRIVATE PLACEMENT BASIS.DUE TO SUDDEN AND STEEP INCREASE IN INTEREST RATES, COMPANY DID NOT ISSUE ANY NCDS.TO CONSIDER FRESH PROPOSAL FOR ISSUE OF NCDS ON PRIVATE PLACEMENT BASIS.  Full Article

Alembic Pharmaceuticals Says JV Gets USFDA Nod For Lidocaine Ointment
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Alembic Pharmaceuticals Ltd ::JV GETS UNITED STATES FOOD AND DRUGS ADMINISTRATION (USFDA) APPROVAL FOR LIDOCAINE OINTMENT USP, 5%..  Full Article

India's Alembic Pharmaceuticals Sept-Qtr Consol Net Profit Rises
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Alembic Pharmaceuticals Ltd ::SEPT QUARTER CONSOL NET PROFIT 2 BILLION RUPEES VERSUS PROFIT OF 1.22 BILLION RUPEES YEAR AGO.SEPT QUARTER CONSOL REVENUE FROM OPERATIONS 11.27 BILLION RUPEES VERSUS 7.89 BILLION RUPEES YEAR AGO.  Full Article

Alembic Pharmaceuticals' JV Aleor Dermaceuticals Clears USFDA Inspection At Karakhadi
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Alembic Pharmaceuticals Ltd ::ALEMBIC PHARMACEUTICALS - JV ALEOR DERMACEUTICALS CLEARED FIRST USFDA INSPECTION OF FORMULATION MANUFACTURING FACILITY AT KARAKHADI.  Full Article

Alembic Pharmaceuticals Gets FDA Tentative Approval For Alogliptin And Metformin Hydrochloride Tablets
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Alembic Pharmaceuticals Ltd ::ALEMBIC PHARMACEUTICALS -GETS USFDA TENTATIVE APPROVAL FOR ALOGLIPTIN AND METFORMIN HYDROCHLORIDE TABLETS, 12.5 MG/500 MG AND 12.5 MG/1000 MG.  Full Article

Alembic Pharmaceuticals Receives Establishment Inspection Report From U.S. FDA
Thursday, 19 Jul 2018 

July 19 (Reuters) - Alembic Pharmaceuticals Ltd ::ALEMBIC PHARMACEUTICALS LTD - HAS RECEIVED ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA FOR INSPECTION CARRIED OUT AT API FACILITY AT KARAKHADI.  Full Article

India's Alembic Pharmaceuticals Gets U.S FDA Tentative Nod For Ticagrelor Tablets
Thursday, 12 Jul 2018 

July 12 (Reuters) - Alembic Pharmaceuticals Ltd ::RECEIVED U.S FDA TENTATIVE APPROVAL FOR TICAGRELOR TABLETS, 90 MG.TABLETS ARE INDICATED TO REDUCE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, OTHERS.  Full Article

Cost of blood pressure drug surges in U.S. after recall

NEW YORK, Oct 16 Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States in September, following a recall of much of the drug's supply.